Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. is a pre-clinical biopharmaceutical company specializing in the discovery and development of therapeutics for stress-related neuropsychiatric and mood disorders. Their lead compound, PT00114, is a synthetic form of teneurin carboxy-terminal associated peptide, designed to dampen overactive stress responses. The company's revenue model is based on the development and commercialization of these therapeutics, with a focus on addressing unmet medical needs in the treatment of stress-related neuropsychiatric and mood disorders.

Products

• PT00114 - Synthetic form of teneurin carboxy-terminal associated peptide